Vice President, Neuroscience

Position Summary

The Vice President and Head of Neuroscience is responsible for enterprise leadership of all aspects of driving the neuroscience portfolio. This includes managing exploratory new target selection, generation of in vitro and in vivo data used to develop pharmacokinetic / pharmacodynamic relationships, and the identification of translational biomarkers to support optimization and clinical development of PROTAC degrader molecules for severe neurologic disorders.

Reports to the Chief Scientific Officer and will be located at our headquarters in New Haven, CT.

• Leads the neuroscience organization with bold new vision, clarity, purpose, and scientific excellence, fostering a culture of innovation and collaboration while advancing and prioritizing high‑impact programs from discovery through clinical development.
• Builds, leads and inspires a high‑performing team through mentorship and development of leadership, scientific and technical capabilities.
• Enables the team to identify, develop, and apply relevant preclinical in‑vivo models to support target validation, lead identification, and optimization. Uses a deep understanding of disease and target biology to guide key scientific decisions and oversees the development of robust target engagement, pathway biology, and biomarker assays that support preclinical pharmacology and translational research.
• Provides strategic oversight for the design, execution, and interpretation of preclinical pharmacology studies to characterize compound activity, establish pharmacokinetic/pharmacodynamic (PK/PD) relationships, and guide candidate optimization. Leverages study outcomes to support translational strategies, inform human dose projections, and advance programs toward clinical development.
• Collaborates cross‑functionally with Research, Translational Sciences, Clinical Development, Regulatory, and Biometrics leaders to define and execute integrated development strategies across the neuroscience portfolio.
• Establishes and leads strategic collaborations with biopharma partners, key scientific investigators, contract research organizations, academic institutions, and external partners to advance translational neuroscience, induced pluripotent stem cell models, biomarker assay capabilities, including assay transfer, method development, qualification, validation, and clinical implementation.
• Provides scientific leadership and strategic oversight for the generation, interpretation, and communication of preclinical pharmacology and translational data to support regulatory submissions, including INDs, CTAs, Investigator Brochures, clinical study protocols, study reports, and laboratory manuals.
• Collaborates across research and development functions to define program strategy, drive execution, and accelerate pipeline progression, leveraging high‑quality in‑vivo pharmacology, biomarker, and translational data to support critical development and portfolio decisions.
• Provides leadership, mentorship, and talent development across the neuroscience organization, fostering a culture of collaboration, trust, accountability, and scientific excellence that enables teams to achieve their highest potential.

• Established scientific reputation in neuroscience and neurodegenerative disease research, with extensive experience applying quantitative and statistical approaches to evaluate disease‑relevant in‑vivo models and translational biomarker endpoints. Recognized through influential publications, scientific leadership, and a strong network of academic, clinical, and industry collaborators.
• Recognized leader with a strong track record of initiating and cultivating high‑value collaborations with academic thought leaders, research consortia, CROs, foundations, and patient advocacy groups to drive scientific innovation, translational research, and therapeutic development in neurodegenerative diseases.
• Leader with extensive experience building and leading multidisciplinary teams focused on preclinical pharmacology and translational medicine, leveraging disease‑relevant models and human biomarker data to drive critical development decisions and…